

PREFERRED DRUG LIST MEETING SCHEDULE

State of Montana
Department of Public Health & Human
Services

Montana Medicaid Pharmacy & Therapeutics (P&T) Committee Meeting

The State of Montana Medicaid P&T Committee will hold a meeting on :

Date: Sept 28, 2011 (Wednesday)
Time: 1:00 pm – 5:00 pm Mountain Time
Location: Best Western Great Northern Hotel
835 Great Northern Blvd, Helena

At this time the Montana Medicaid P&T Committee will review the following PDL drug classes:

All drugs reviewed pertain to oral drugs unless otherwise indicated

The Department proposes no changes to **GROUP 1** as all available chemical entities are preferred :

- GLAUCOMA- CARBONIC ANHYDRASE INHIBITORS

The Department proposes no changes to the Formulary Committee's clinical recommendations.

The following classes will not be reviewed unless manufacturers submit **NEW** information:

- SKELETAL MUSCLE RELAXANTS
- HEMATOPOIETIC AGENTS
- ADHD//CNS STIMULANTS –
- CALCITONINS
- GROWTH HORMONES
- OTIC QUINOLONES
- GLAUCOMA- ALPHA 2 ADRENERGICS
- GLAUCOMA- BETA BLOCKERS & COMBOS
- GLAUCOMA- PROSTAGLANDIN AGONISTS
- ALPHA BLOCKERS for BPH
- URINARY TRACT ANTISPASMODICS

The Department will review the following classes as **NEW** information is known to exist:

- ANTIMIGRAINE AGENTS – Cambia, Alsuma
- LONG ACTING NARCOTICS~Butrans
- TOPICAL ANALGESICS/ANESTHETICS – NEW
- ELECTROLYTE DEPLETERS - Phoslyra
- ANTICOAGULANTS– Pradaxa, warfarin, Xarelto
- PLATELET INHIBITORS - Brilinta
- NOVEL ANTIDEPRESSANTS~Oleptro, Viibryd
- SSRIs – FDA Update
- ATYPICAL ANTIPSYCHOTICS ~Latuda
- SEDATIVE HYPNOTICS – NEW
- HEPATITIS C AGENTS- FULL REVIEW
- BONE RESORPTION INH,BISPHOSPHONATES and OTHER-Atelvia Prolia, Forteo, Evista
- OPHTHALMIC ALLERGIC CONJUNCTIVITS - Lastacaft
- OPHTHALMIC QUINOLONES~Zymaxid, Moxeza
- ANDROGEN HORMONE INHIBITORS & COMBO - Jalyn

Public Testimony will be taken into consideration in the committee's recommendations as to which drugs should be given preferred status in the above listed classes of medications for the state's Medicaid program. Sign-up for public comment will occur between 12:30pm -12:55 pm outside the Conference Room. Please see the **General Procedures for Public Comment**.

Clinical Information: New clinical information (in electronic format in PDF in the AMCP style dossier or desired style) may be sent by e-mail on the drug classes listed above by Sept 14, 2011 to:

David Campana, R.Ph., Montana Department of Public Health & Human Services

DCampana@mt.gov and pdl@mt.gov

Note: If you wish to submit clinical information pertaining to the PDL review process for drugs within the designated classes, peer-reviewed literature including off label peer-reviewed studies or AMCP style – dossiers will be accepted in electronic PDF format **only**. Please note that all information sent is subject to public disclosure and that proprietary and confidential material should not be sent and that the sender accepts responsibility for all information sent. All information sent will be posted on a public website for viewing. Department Personnel will not sign manufacturer release of information waivers.

Montana Medicaid
Department of Public Health and Human Services
P&T Committee Meeting

General Procedures for Public Comment

1. Thirty minutes prior to the beginning of the P&T Committee Meeting, a sign up sheet for Public Comment will be posted for Pharmaceutical Manufacturers and Special Interest Groups for each Drug Class to be reviewed.
2. Sign up will close 5 minutes prior to the beginning of the P&T Committee Meeting.
3. Speakers will be assigned on a first come basis respective to each Drug Class discussion.
4. Speakers will be asked to present **NEW INFORMATION ONLY** on their corresponding product or interest.
 - a. New Information is considered the following: new product in the drug class, new indication received or new studies released since the last review, excluding placebo only studies. New studies must be separately submitted in electronic format no later than two weeks prior to the scheduled meeting. In classes designated as *NEW* on the agenda no review has previously been performed, therefore all information is considered new.
 - b. Public comment will be allowed for up to 10 minutes to present new information about their product. However, please be respectful of your other colleagues and also of the Committee's time. Please do not take 10 minutes if it is not needed. The P&T Committee Coordinator has the option to end a speaker's comment time if the information is not relevant to the topic of discussion.
 - c. Speakers must state their name, their affiliation, and whom they are speaking on behalf of or on request of, with any funding or payment agreements disclosed. Any studies cited during the presentation should be referenced with the primary source of funding included.
 - d. Handouts are limited to two (2) pages (paper size: 8.5" by 11", one side only) of documentation. Access to computers or other technology presentation devices for slide presentations will not be available during this comment period.
 - e. Public Comment will be limited to clinical and social comments; pricing or financial information regarding products and outcomes is not permitted. The Committee will be utilizing clinical information only.
 - f. The speakers presenting handouts are asked to provide at least thirty (30) copies that will be distributed by Foundation staff to the P&T Committee members, State staff and for public distribution.
 - g. Copies will be collected by Foundation staff members at the time of sign-up.
 - h. The State, FHSC and the P&T Committee will be allowed to ask questions if needed during the presentation or after for clarification or discussion. Presenters will only be allowed to answer questions when specifically requested to do so by the Committee during the remainder of the meeting.
 - i. It is not permissible for presenters to interject or ask questions to P&T Committee members during the session.
5. Individual products may only be represented by one presentation. For example, a product jointly ventured by two pharmaceutical companies can only be represented once.

Note: These procedures may be revised at the discretion of the Department.